New Information on Topical Calcineurin Inhibitors
> 1/30/2006 2:25:36 PM

Last week the Food and Drug Administration approved new labeling for Elidel Cream, a Novartis product often used to treat eczema.

From the FDA News Release:
"The labeling will be updated with a boxed warning about a possible risk of cancer and a Medication Guide (FDA-approved patient labeling) will be distributed to help ensure that patients using these prescription medicines are aware of this concern. The new labeling also clarifies that these drugs are recommended for use as second-line treatments. This means that other prescription topical medicines should be tried first. Use of these drugs in children under 2 years of age is not recommended."

Read the rest of the news release here.

If you or someone that you know are currently using Elidel Cream or another topical calcineurin inhibitor you should contact the prescribing physician immediately to make sure that it is the best option for you.

No comments yet.

Post Your Comments

Post a comment
Email Address:
Verification Code:
Input the 8 characters you see above:


Drug Abuse
Sexual Addiction
Eating Disorders
Alzheimer's Disease

About TOL | Contact Us | Defining Behavioral Fitness | For Healthcare Professionals | Links | Privacy Policy